The Filing Desk

Kura Oncology

KURA · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

KURA · Last close · November 13, 2026
$7.77
Value Kura Oncology yourself

Kura Oncology's revenue rose 25.2% to $68 million in fiscal 2025. Its operating margin was −449.9%, down from −358.6% a year earlier. Free cash flow was −$71 million, against $134 million a year earlier. The diluted share count rose 1.8%.

Kura Oncology, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001193125-26-092567 Updated
Revenue
$68M
25.2%
Operating margin
−449.9%
91.4 pts
Net income
−$279M
 
Free cash flow
−$71M
$134M a year earlier
Return on equity
−94.8%
51.9 pts
Market cap
$698M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Kura Oncology does

Kura Oncology is a drug company that develops cancer medicines taken as pills. On November 13, 2025, the US Food and Drug Administration approved its first product, KOMZIFTI (ziftomenib), for adults with a type of blood cancer called relapsed or refractory acute myeloid leukemia (AML) that carries a specific gene change, called an NPM1 mutation, and who have no satisfactory alternative treatments. Kura says it is the first menin inhibitor approved by the FDA that is taken once a day by mouth.

Kura is still testing ziftomenib to see whether it works earlier in AML treatment and alongside other therapies, including in two late-stage trials in newly diagnosed patients. It is also testing it with imatinib for gastrointestinal stromal tumors. It has other programs: a next-generation menin inhibitor for diabetes and heart and metabolic conditions, and an experimental drug called darlifarnib that it is testing with other targeted therapies in solid tumors such as kidney, lung, colorectal and pancreatic cancers.

Kura says it has changed from a research company into a commercial-stage one, and it has little experience selling a drug. Its revenue will depend mostly on KOMZIFTI sales in the United States. It plans to move its drugs forward through its own development, partnerships and acquisitions.

Its biggest risks, as it describes them

  • Its revenue depends heavily on successful sales of KOMZIFTI in the United States.
  • KOMZIFTI may not win enough acceptance from doctors, patients and insurers, or its market may be smaller than expected.
  • Limited experience as a commercial company, so selling the drug may go less well than planned.
  • Losing or failing to widen its FDA approval, and results in real-world use that differ from its trials.
  • Competing drugs, and the need to prove ziftomenib in combination and earlier-treatment settings.
From Kura Oncology's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Kura Oncology lost money in fiscal 2025: a net loss of $279 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments518438424727667
Debt incl. finance leases—991010
Net debt (negative means net cash)—−429−415−718−658
Net debt to EBITDA—————
Debt to equity—0.0x0.0x0.0x0.1x
Interest coverage−314.1x−610.8x−107.0x−119.3x−200.8x
Current ratio23.3x18.6x12.3x9.5x6.1x
Quick ratio23.3x18.6x12.3x9.5x6.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Kura Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Kura Oncology says to expect

  • Collaboration revenue guidance: 2026 and later yearsKura has updated its 2026 collaboration revenue guidance to $40 million to $45 million for 2026 and is maintaining guidance of $90 million to $110 million in each of 2027 and 2028.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 10, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Kura Oncology reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score—4 of 83 of 8
Rule of 40——−79.5%
Altman Z''6.161.45−2.37
Accruals ratio−6.1%−51.0%−28.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets—PassFail
F-score—4 of 83 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Kura Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Kura OncologyFY2525.2%−449.9%−104.8%——3
Viridian TherapeuticsFY2523,359.9%−512.9%−390.8%———Compare
Nuvation BioFY25699.0%−338.7%−288.4%———Compare
Tango TherapeuticsFY2548.3%−178.4%−224.3%———Compare
Eton PharmaceuticalsFY25104.9%−1.1%12.8%−1.9%1.4x4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue———————05468
Revenue growth—————————25.2%
Gross profit——————————
Research and development—264748608593115170251
Operating income——————−140−166−193−304
Net income−28−35−60−63−90−130−136−153−174−279
Diluted EPS (US$)−1.47−1.52−1.72−1.51−1.69−1.97−2.03−2.08−2.02−3.18
Diluted shares (millions)19233542536667738688
Cash flow
Cash from operations−25−28−49−55−70−105−110−125134−64
Capital expenditure————211007
Free cash flow————−72−106−111−125134−71
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation2499132426283437
Balance sheet at fiscal year end
Cash and short-term investments1093179237633518438424727667
Debt incl. finance leases77—87—991010
Total assets7096182242647534456449760738
Total liabilities1316212336273652346564
Shareholders' equity5780161219611507420397414174
Margins and ratios
Gross margin——————————
Operating margin————————−358.6%−449.9%
Net margin————————−322.9%−412.9%
Free cash flow margin————————248.4%−104.8%
Rule of 40 (growth + FCF margin)—————————−79.5%
Return on capital—−113.0%————————
Return on equity−39.7%−51.8%−50.2%−33.2%−21.6%−23.4%−29.3%−37.3%−42.9%−94.8%
Return on assets−35.1%−42.8%−43.5%−29.8%−20.2%−22.1%−27.4%−33.7%−28.8%−37.2%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Kura Oncology's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Kura Oncology.